Research programme: hepatitis B therapy - China Botanic PharmaceuticalAlternative Names: Total alkaloids of Sophora flavescens - China Botanic Pharmaceutical
Latest Information Update: 16 Jul 2016
At a glance
- Originator China Botanic Pharmaceutical
- Class Alternative medicine
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatitis-B in China
- 31 Jul 2011 Preclinical trials in Hepatitis B in China (unspecified route)
- 01 Apr 2010 Early research in Hepatitis B in China (unspecified route)